Latest aldafermin data in NASH weigh on NGM shares

NGM shed $2.77 (20%) to $10.78 on Monday as investors appeared underwhelmed by Phase II data for aldafermin in NASH.

Interim 24-week data from cohort 4 of an adaptive Phase II trial showed that treatment with a 1

Read the full 376 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE